Anika Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Anika Therapeutics generated cash of -$1,788,000, which is less than the previous year. Cash used in financing activities reached the amount of -$6,324,000 last year. Net change in cash is therefore -$13,460,000.
Cash Flow
| 2014 | 39.97M | -8.30M | 5.33M |
|---|---|---|---|
| 2015 | 39.06M | -30.22M | 1.92M |
| 2016 | 23.80M | -6.76M | -23.34M |
| 2017 | 40.81M | -12.48M | 314K |
| 2018 | 34.91M | -50.25M | -28.90M |
| 2019 | 37.00M | 39.69M | -8.14M |
| 2020 | 13.06M | -71.26M | -3.77M |
| 2021 | 8.39M | -3.11M | -6.77M |
| 2022 | 4.40M | -7.48M | -4.85M |
| 2023 | -1.78M | -5.42M | -6.32M |
ANIK Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 86.32M | 94.38M | 95.81M | 157.46M | 89.04M | 133.25M | 104.26M | 110.70M | 100.15M | 63.33M |
Operating activities | ||||||||||
Net income | -82.66M | -14.85M | 4.13M | -23.98M | 27.19M | 18.72M | 31.81M | 32.54M | 30.75M | 38.31M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 14.21M | 14.48M | 14.31M | 13.46M | 5.99M | 5.91M | 4.29M | 3.73M | 3.77M | 4.70M |
Stock-based compensation expense | 15.24M | 14.31M | 11.08M | 5.38M | 6.08M | 0 | 5.80M | 3.39M | 2.22M | 1.60M |
| Deferred income tax benefit | 15.24M | 14.31M | 11.08M | 5.38M | 6.08M | 0 | 5.80M | 3.39M | 2.22M | 1.60M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | -1.30M | -5.63M | -6.21M | 5.85M | -1.83M | 2.91M | 2.67M | -6.20M | -4.99M | 897.56K |
Inventories | -11.39M | -6.87M | -6.61M | -14.17M | -5.58M | -7.57M | -6.52M | -1.73M | -2.93M | -1.97M |
Accounts payable | -11K | 1.96M | -1.1M | 822K | 767K | -1.67M | 3.89M | -5.05M | 5.62M | -749.60K |
Cash generated by operating activities | -1.78M | 4.40M | 8.39M | 13.06M | 37.00M | 34.91M | 40.81M | 23.80M | 39.06M | 39.97M |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | -2.02M | -20.03M | -103.84M | -91.60M | -45M | -39.24M | -45.25M | -26.75M |
Investments In Property Plant And Equipment | -5.42M | -7.48M | -5.14M | -1.62M | -2.82M | -4.65M | -8.98M | -14.01M | -9.22M | -1.55M |
Acquisitions Net | 0 | 0 | -476K | -94.60M | -42.51M | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -5.42M | -7.48M | -3.11M | -71.26M | 39.69M | -50.25M | -12.48M | -6.76M | -30.22M | -8.30M |
Financing activities | ||||||||||
Common Stock Issued | 0 | 681K | 1.12M | 1.52M | 0 | 2.88M | 314K | 1.00M | 1.07M | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | -5M | -934K | -486K | -262K | -30M | -30M | 0 | -25M | 0 | -6.34M |
Repayments of term debt | 0 | -284K | -201K | -50.55M | 0 | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | -6.32M | -4.85M | -6.77M | -3.77M | -8.14M | -28.90M | 314K | -23.34M | 1.92M | 5.33M |
Net Change In Cash | -13.46M | -8.05M | -1.43M | -61.64M | 68.42M | -44.21M | 28.99M | -6.44M | 10.55M | 36.82M |
Cash at end of period | 72.86M | 86.32M | 94.38M | 95.81M | 157.46M | 89.04M | 133.25M | 104.26M | 110.70M | 100.15M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |